Kinnate Biopharma Bilan de santé

Santé financière contrôle des critères 6/6

Kinnate Biopharma possède un total de capitaux propres de $172.4M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $190.7M et de $18.3M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$167.58m
Fonds propres	US$172.42m
Total du passif	US$18.29m
Total des actifs	US$190.71m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 6KB ( $170.3M ) dépassent ses passifs à court terme ( $15.8M ).

Passif à long terme: Les actifs à court terme de 6KB ( $170.3M ) dépassent ses passifs à long terme ( $2.5M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 6KB est sans dette.

Réduire la dette: 6KB n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 6KB dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 6KB dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 39.1 % chaque année

Kinnate Biopharma Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Kinnate Biopharma Files Form 15

Recent updates

Kinnate Biopharma Files Form 15

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Kinnate Biopharma Inc. Announces Workforce Restructuring

New minor risk - Market cap size

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

Kinnate Biopharma Inc. Appoints Jill DeSimone as Independent Director, Effective on March 1, 2023

Kinnate Biopharma Inc. to Present Trials in Progress Poster for Its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

High number of new and inexperienced directors

Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor

Kinnate Biopharma Inc. Announces Pipeline Update

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from Russell 2000 Growth Index

Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022

High number of new and inexperienced directors

Kinnate Biopharma Inc., Annual General Meeting, Jun 10, 2022

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Its FGFR Inhibitor Product Candidate, KIN-3248

Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

Chief Medical Officer recently bought €308k worth of stock

Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation At the American Association for Cancer Research Annual Meeting

Kinnate Biopharma Inc. to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Kinnate Biopharma Inc. Announces U.S Food and Drug Administration Clearance of Investigational Drug Application for KIN-3248

Kinnate Biopharma Inc. Announces That the First Patient Has Commenced Treatment in its Phase 1 KN-8701 Clinical Trial

Director Stephen Kaldor has left the company

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines